Non-small cell lung cancer stage III
RecruitingStudy on the Effectiveness of Cemiplimab, Carboplatin, and Paclitaxel for Unfit or Elderly Patients with Unresectable Stage III Non-Small Cell Lung Cancer
Study on the Effectiveness of Cemiplimab, Carboplatin, and Paclitaxel for Unfit or Elderly Patients with Unresectable Stage III Non-Small Cell Lung Cancer
- Disease:Non-small cell lung cancer stage III
- Substances:CarboplatinCemiplimab+1
France- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:Intergroupe Francophone De Cancerologie Thoracique








